直接抗病毒药物治疗丙型肝炎病毒清除可降低肝细胞癌风险
该回顾性队列研究纳入美国退伍军人医疗系统1999年1月1日至2015年12月31日启动抗病毒治疗的62354例丙型肝炎病毒感染者,随访至2017年6月15日,中位随访6.1年。结果显示,直接抗病毒药物诱导的持续病毒学应答与肝细胞癌风险显著降低相关,且直接抗病毒药物治疗未较干扰素治疗增加肝细胞癌风险。
要点
- 持续病毒学应答与肝细胞癌风险显著降低相关,直接抗病毒药物方案调整后风险比为0.29。
- 肝硬化且治疗失败者肝细胞癌发生率最高,为每100患者年3.25例。
- 直接抗病毒药物治疗未较干扰素治疗增加肝细胞癌风险。
核心结论
- 直接抗病毒药物诱导的持续病毒学应答与肝细胞癌风险降低71%相关,且直接抗病毒药物治疗未较干扰素治疗增加肝细胞癌风险。
研究设计与样本
- 回顾性队列研究,纳入美国退伍军人医疗系统1999年1月1日至2015年12月31日启动抗病毒治疗的62354例患者,其中干扰素单药方案35871例(58%)、直接抗病毒药物联合干扰素方案4535例(7.2%)、直接抗病毒药物单药方案21948例(35%),随访至2017年6月15日,平均随访6.1年。
主要发现
- 共诊断3271例肝细胞癌新发病例,均在启动抗病毒治疗至少180天后诊断。
- 肝细胞癌发生率在肝硬化且治疗失败组为每100患者年3.25例,肝硬化且持续病毒学应答组为1.97例,无肝硬化且治疗失败组为0.87例,无肝硬化且持续病毒学应答组为0.24例。
- 多因素模型中,持续病毒学应答与肝细胞癌风险显著降低相关:直接抗病毒药物单药方案调整后风险比0.29(95%置信区间0.23-0.37),直接抗病毒药物联合干扰素方案调整后风险比0.48(95%置信区间0.32-0.73),干扰素单药方案调整后风险比0.32(95%置信区间0.28-0.37)。
- 与干扰素单药方案相比,接受直接抗病毒药物单药或直接抗病毒药物联合干扰素方案未与肝细胞癌风险增加相关。
关键数值与推荐
- 持续病毒学应答与肝细胞癌风险降低相关,直接抗病毒药物单药方案调整后风险比0.29(95%置信区间0.23-0.37),直接抗病毒药物联合干扰素方案调整后风险比0.48(95%置信区间0.32-0.73),干扰素单药方案调整后风险比0.32(95%置信区间0.28-0.37)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is unclear whether direct-acting antiviral (DAA) treatment-induced sustained virologic response (SVR) reduces the risk of hepatocellular carcinoma (HCC) in patients with HCV infection. Therefore, in the current study, our aim was to determine the impact of DAA-induced SVR on HCC risk. METHODS: We identified 62,354 patients who initiated antiviral treatment in the Veterans Affairs (VA) national healthcare system from 1 January 1999 to 31 December 2015, including 35,871 (58%) interferon (IFN)-only regimens, 4,535 (7.2%) DAA + IFN regimens, and 21,948 (35%) DAA-only regimens. We retrospectively followed patients until 15 June 2017 to identify incident cases of HCC. We used Cox proportional hazards regression to determine the association between SVR and HCC risk or between type of antiviral regimen (DAA-only vs. DAA + IFN vs. IFN-only) and HCC risk. RESULTS: We identified 3,271 incident cases of HCC diagnosed at least 180 days after initiation of antiviral treatment during a mean follow-up of 6.1 years. The incidence of HCC was highest in patients with cirrhosis and treatment failure (3.25 per 100 patient-years), followed by cirrhosis and SVR (1.97), no cirrhosis and treatment failure (0.87), and no cirrhosis and SVR (0.24). SVR was associated with a significantly decreased risk of HCC in multivariable models irrespective of whether the antiviral treatment was DAA-only (adjusted hazard ratio [AHR] 0.29; 95% CI 0.23-0.37), DAA + IFN (AHR 0.48; 95% CI 0.32-0.73) or IFN-only (AHR 0.32; 95% CI 0.28-0.37). Receipt of a DAA-only or DAA + IFN regimen was not associated with increased HCC risk compared with receipt of an IFN-only regimen. CONCLUSIONS: DAA-induced SVR is associated with a 71% reduction in HCC risk. Treatment with DAAs is not associated with increased HCC risk compared with treatment with IFN. LAY SUMMARY: It was unclear whether direct-acting antiviral treatment-induced sustained virologic response reduces the risk of liver cancer in patients with HCV infection. We demonstrated that eradication of HCV infection with direct-acting antiviral agents reduces the risk of liver cancer by 71%.
引用
- Ioannou GN, Green PK, Berry K, et al. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017. PMID: 28887168. doi:10.1016/j.jhep.2017.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。